Immune environment of high-TIL breast cancer: triple negative and hormone receptor positive HER2 negative
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Immune environment of high-TIL breast cancer: triple negative and hormone receptor positive HER2 negative ; volume:10 ; number:1 ; day:26 ; month:11 ; year:2024 ; pages:1-9 ; date:12.2024
npj Breast cancer ; 10, Heft 1 (26.11.2024), 1-9, 12.2024
- Urheber
-
Shin, Su-Jin
Park, Inho
Go, Heounjeong
Ko, Jiwon
Lee, Yangkyu
Kim, Jee Hung
Ahn, Sung Gwe
Jeong, Joon
Bae, Soong June
Cha, Yoon Jin
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41523-024-00712-9
- URN
-
urn:nbn:de:101:1-2502112130098.916797170558
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Shin, Su-Jin
- Park, Inho
- Go, Heounjeong
- Ko, Jiwon
- Lee, Yangkyu
- Kim, Jee Hung
- Ahn, Sung Gwe
- Jeong, Joon
- Bae, Soong June
- Cha, Yoon Jin
- SpringerLink (Online service)
Ähnliche Objekte (12)
Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?